Navigation Links
OncoSec Closes $7.75 Million Public Offering
Date:3/28/2012

SAN DIEGO, March 28, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering.  Additionally, investors received Warrants to purchase up to 31,000,000 shares of common stock at an exercise price of $0.35 per share for a term of five years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering were $7.75 million and net proceeds, after deducting the placement agent's fee and estimated offering expenses payable by OncoSec, were approximately $7.2 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the transaction.  Roth Capital Partners, LLC served as financial advisors to the Company in the offering.

About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and ot
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoSec to Present at 10th Annual BioPartnering North America
2. OncoSec Medical Reports Third Quarter 2011 Financial Results
3. OncoSec Announces Clinical Leadership Appointments
4. OncoSec Announces Leadership Team Appointments
5. OncoSec Medical Featured in Medical Device Daily
6. OncoSec Medical Appoints Punit Dhillon as President and CEO
7. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
9. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
10. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
11. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... ... 2015 , ... As part of its 2015 growth plan and as a follow up to ... business units, Whitehouse Laboratories is pleased to announce that it has begun construction on a ... Excellence and will be strictly dedicated to basic USP 51, USP 61, and USP 62 ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... adept at climbing through difficult terrain using an intricate adhesive ... how they switch on their unique system of traction. ... South Carolina have discovered that the geckos, amazing grip is ... adhesive research will be published Wed., Aug. 5, at 00:001 ...
... , , SOUTH SAN ... PARD ), a biopharmaceutical company focused on oncology, today reported financial ... a corporate update. , , "During the ... 2 picoplatin data from our colorectal and prostate cancer programs. ...
... NEW YORK, Aug. 4 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... 8:30 a.m. EDT to discuss the second quarter 2009 financial results and ... Officer of the Company, will host the call. Keryx will announce ... issued prior to the call. , , In order ...
Cached Biology Technology:New angle on gecko research 2Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 8Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT 2
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... humans: pubic lice, Pthirus pubis , and human head ... in BioMed Central,s open access Journal of Biology ... In the article, Robert Weiss from University ... pondering the question of why lice would separate into two ...
... In a fight against respiratory infections, the body typically ... productive cough. But new research suggests that the influenza virus ... lungs, interfering with the supply of oxygen to the rest ... to eliminate the virus, but this research suggests that it,s ...
... The genome of a marine bacterium living 2,500 meters ... life adapts in extreme thermal and chemical gradients, according ... PLoS Genetics , an open-access publication published by ... on the bacterium Nautilia profundicola , a microbe ...
Cached Biology News:Study: Fluid buildup in lungs is part of the damage done by the flu 2Study: Fluid buildup in lungs is part of the damage done by the flu 3Genetic adaptations key to microbe's survival in challenging environment 2
... Kit, 500 reactions. Prepare circular DNA ... h.Generate microgram quantities of template DNA ... amplified DNA directly for cycle sequencing ... M13 liquid cultures, colonies, plaques, or ...
...
Request Info...
Spaced cover glasses to promote effective hybridization...
Biology Products: